Relation between HIV-1 syncytium inhibition antibodies and clinical outcome in children.
Relation between HIV-1 syncytium inhibition antibodies and clinical outcome in children.
复制标题
HIV-1 合胞体抑制抗体与儿童临床结果之间的关系。
DOI：
10.1016/0140-6736(91)92660-t
复制
发表时间：
1991
期刊：
影响因子：
--
通讯作者：
Andiman,WA
中科院分区：
文献类型：
--
作者：
Brenner,TJ;Dahl,KE;Olson,B;Miller,G;Andiman,WA
Syncytium formation, a feature of HIV-1-induced cytopathology, allows the virus to propagate through cell-to-cell spread. An assay has been developed to measure antibodies (syncytium inhibition, SI) that inhibit this process. Two cell lines were used: the indicator cells, which are not HIV-1 infected, bear CD4 receptors on their surface; the fusogenic HIV-1 infected cells, which do not release virus but are responsible for initiating syncytium formation, are free of CD4 receptors. Co-cultivation of about 105of each of these cells induces the emergence of 70-100 multinucleated giant cells within 48 h. Sera from 34 children born to HIV-1-infected mothers were tested by western blot (WB) and SI assay. SI antibodies were detected in the blood of 15 (65%) of 23 WB-positive children and in none of 11 WB-negative children. There were striking differences in prevalence and titre of SI antibodies in children with lymphocytic interstitial pneumonitis (LIP) compared with those with opportunistic infections (01). All 8 children with LIP had SI antibodies ranging in titre from 40 to > 320. By contrast, only 2 of 7 with 01 had SI antibodies, in both of whom the SI titre was 20 (p<0·05). No sera from children who had seroreverted contained SI antibodies. The findings point to the need to identify the specific HIV-I peptides or epitopes responsible for syncytium formation since SI antibodies correlate with clinical outcome in children.
